Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 3/20 | 0.35 |
| ▸ | PLK1 | P53350 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.33 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.33 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415904 | 0.86 | NEK2 (0.34) | NEK2PLK1LRRK2YTHDC1RPS6KA5 | |
| SCHEMBL10212386 | 0.85 | LRRK2 (0.34) | NEK2PLK1LRRK2MAPK1RPS6KA5 | |
| SCHEMBL11938830 | 0.84 | NEK2 (0.39) | NEK2PLK1LRRK2MAPK1ITK | |
| SCHEMBL10212410 | 0.80 | ADORA2A (0.34) | ADORA2AADORA2B | |
| Nitrous Acid SCHEMBL11021890 | 0.78 | NEK2 (0.35) | NEK2PLK1LRRK2CYP1A2MAPK1 | |
| Nitrous Acid SCHEMBL11021891 | 0.78 | NEK2 (0.35) | NEK2PLK1LRRK2CYP1A2MAPK1 | |
| SCHEMBL182614 | 0.77 | NEK2 (0.51) | NEK2PLK1CYP1A2ITKRPS6KA5 | |
| SCHEMBL182613 | 0.77 | NEK2 (0.51) | NEK2PLK1CYP1A2ITKRPS6KA5 | |
| SCHEMBL10212389 | 0.75 | NEK2 (0.52) | NEK2MAPK1 | |
| SCHEMBL181661 | 0.73 | KIF11 (0.46) | CYP1A2MAPK1MAP2K4MAPKAPK3MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9018234-B2 | Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8642595-B2 | Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20130005773-A1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20120270905-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270905-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | MET, DCK, RET | NEK2 447/4885PLK1 2190/4885LRRK2 949/4885 |
| US-20130005773-A1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | MET, RET, ABL1 | NEK2 629/4885PLK1 2206/4885LRRK2 580/4885 |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, ERBB4, RET | NEK2 827/4885PLK1 1039/4885LRRK2 538/4885 |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | MET, RET, ERBB2 | NEK2 1049/4885PLK1 1152/4885LRRK2 333/4885 |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | MET, DCK, RET | NEK2 906/4885PLK1 2552/4885LRRK2 644/4885 |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BMX, MET, ABL1 | NEK2 1730/4885PLK1 3162/4885LRRK2 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.